SCHEMBL7052381

SCHEMBL7052381

CCOC(=O)C1(SCC=Cc2ccc(Cc3nc(-c4ccc(N(C)C)cc4)oc3C)o2)CCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.38
TARBP2 Q15633 5/20 0.33
PPARG P37231 2/20 0.33
PPARA Q07869 2/20 0.33
ALDH1A1 P00352 4/20 0.33
TSHR P16473 3/20 0.33
MAPT P10636 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
LMNA P02545 2/20 0.33
HTT P42858 1/20 0.33
ALOX15 P16050 1/20 0.33
KDM4E B2RXH2 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.32
USP2 O75604 1/20 0.32
POLB P06746 2/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32
TP53 P04637 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7052376 1.00 HSD17B10 (0.38) HSD17B10TARBP2PPARGPPARAALDH1A1
SCHEMBL6776575 0.90 PPARA (0.37) HSD17B10PPARGPPARAALDH1A1SMN1; SMN2
SCHEMBL6776581 0.90 PPARA (0.37) HSD17B10PPARGPPARAALDH1A1SMN1; SMN2
SCHEMBL6776378 0.85 HPGD (0.38) HSD17B10PPARGPPARAALDH1A1TSHR
SCHEMBL6776383 0.85 HPGD (0.38) HSD17B10PPARGPPARAALDH1A1TSHR
SCHEMBL6777053 0.84 LATS1 (0.31)
SCHEMBL6777048 0.84 LATS1 (0.31)
SCHEMBL6775374 0.81 HSD17B10 (0.38) HSD17B10TARBP2PPARGPPARAALDH1A1
SCHEMBL6775375 0.81 HSD17B10 (0.38) HSD17B10TARBP2PPARGPPARAALDH1A1
SCHEMBL6776046 0.78 KDM4E (0.39) HSD17B10PPARGPPARAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225145-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. 2003-12-04 US claimed
US-6589969-B1 A peroxisome proliferator activated receptor regulator containing a compound of formula (I) Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive ONO PHARMACEUTICAL CO., LTD. (JP) 2003-07-08 US claimed
EP-1122255-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-08-08 EP claimed
US-6821994-B2 A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR REGULATOR, AN OXAZOL-4-YL-METHYLFURAN-2-YL-2-PROPENYLTHIO- OR SULFONYL- OR SULFINYL-ACETIC ACID OR METHYL ESTER ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-23 US disclosed
US-20030225145-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. 2003-12-04 US disclosed
US-6589969-B1 A peroxisome proliferator activated receptor regulator containing a compound of formula (I) Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive ONO PHARMACEUTICAL CO., LTD. (JP) 2003-07-08 US disclosed
EP-1122255-A1 CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225145-A1 Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient PPARA, PPARG, PPARD HSD17B10 111/4885TARBP2 3393/4885PPARG 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.